ATOSSA THERAPEUTICS, INC.

For the period ended Dec 31, 2025. Filed Mar 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 25, 2026

ATOS$2.13+0.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(amounts in thousands, except share and per share data)

	As of December 31,
	2025	2024
Assets
Current assets
Cash and cash equivalents	$41,299	$71,084
Restricted cash	110	110
Prepaid materials	3,081	2,098
Prepaid expenses and other current assets	1,128	1,165
Total current assets	45,618	74,457
Other assets	1,990	1,987
Total assets	$47,608	$76,444
Liabilities and stockholders' equity
Current liabilities
Accounts payable	$4,293	$679
Accrued expenses	1,307	919
Payroll liabilities	1,558	1,862
Other current liabilities	1,097	1,507
Total current liabilities	8,255	4,967
Total liabilities	8,255	4,967
Commitments and contingencies (Note 13)	—	—
Stockholders' equity
Series B convertible preferred stock - $0.001 par value; 10,000,000 shares authorized; 577 and 582 shares issued and outstanding as of December 31, 2025 and 2024, respectively	—	—
Common stock - $0.18 par value; 350,000,000 shares authorized 8,611,361 and 8,611,266 shares issued and outstanding as of December 31, 2025 and 2024, respectively	1,550	1,550
Additional paid-in capital	285,840	283,194
Treasury stock, at cost; 88,003 shares of common stock at December 31, 2025 and 2024, respectively	(1,475)	(1,475)
Accumulated deficit	(246,562)	(211,792)
Total stockholders' equity	39,353	71,477
Total liabilities and stockholders' equity	$47,608	$76,444

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.